Search Results
Mar 09, 2026, 10:50 ET CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
multimedia:https://www.prnewswire.com/news-releases/cns-drug-developers-add-pharma-veterans-as-sector-nears-first-fda-decisions-302708269.html
More news about: USA News Group
Mar 09, 2026, 09:15 ET Tasman Therapeutics to Participate in the Stifel 2026 Virtual CNS Forum
Tasman Therapeutics announced today that Dan Browne, CEO and Dr Peter Surman, Chief Scientific Officer, will present at the Stifel 2026 Virtual CNS Forum discussing R-107, a proprietary Phase 3 ready ketamine oral dose as a therapy for patients with hard-to-treat depression. The webcast will
More news about: Tasman Therapeutics
Mar 09, 2026, 04:46 ET Guizhou's Bridges: A New Tourism Landmark in Southwest China
GUIYANG, China, March 9, 2026 /PRNewswire/ -- A news report from CNS: Nestled among the karst mountains of southwest China, a series of super bridges spanning deep gorges and reaching toward the clouds are transforming Guizhou's
More news about: CNS
Mar 07, 2026, 17:51 ET TTW Picks Best 50 Heritage Travel Destinations in the World for 2026
AustraliaSydney Opera House – Sydney Kingsford Smith Airport (SYD)Great Barrier Reef – Cairns Airport (CNS) / Hamilton Island Airport (HTI)Heard and McDonald Islands – Access via Hobart Airport (HBA, Tasmania)Tasmanian Wilderness –
More news about: Travel And Tour World
Mar 06, 2026, 08:48 ET RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Mar 06, 2026, 07:46 ET The International Society for CNS Drug Development (ISCDD) Honors Suresh Durgam, MD, with Prestigious Leadership Award at 24th Annual Meeting
behalf of the ISCDD leadership.Dr. Durgam said: "I am honored to accept the International Society for CNS Drug Development Leadership Award from ISCDD who represent the leaders in CNS drug development. This recognition reflects the dedication of many team members including researchers and healthcare
More news about: International Society for CNS Drug Development
Mar 05, 2026, 16:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Mar 05, 2026, 14:25 ET RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST
characterized its RGX-111 gene therapy candidate as recently as January 2025. By January 28, 2026, the FDA had placed a clinical hold on the program after a CNS tumor was discovered in a trial participant, and RGNX shareholders lost $2.40 per share in a single trading session.
More news about: SueWallSt.com
Mar 05, 2026, 09:37 ET Kenox Pharmaceuticals Inc. Announces Clinical Manufacturing Readiness for Nasal and Inhaled Drug Products
bioequivalence support.With its expanded capabilities, Kenox is positioned to support programs across a broad range of therapeutic areas, including CNS indications leveraging nose‑to‑brain delivery (psychiatry, Alzheimer's disease, ALS, Parkinson's disease, traumatic brain injury), pulmonary
More news about: Kenox Pharmaceuticals Inc.
Mar 05, 2026, 07:05 ET REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
In January 2026, the FDA placed a clinical hold on RGX-111 following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study.The FDA also placed a clinical hold on RGX-121 citing similarities to RGX-111, study
More news about: REGENXBIO Inc.
Mar 05, 2026, 07:00 ET Corero Network Security Named a 'Star' in MarketsandMarkets DDoS Protection & Mitigation Security Market Report
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a leader in real-time DDoS protection and service availability, today announced it has been named a "Star" in the MarketsandMarkets
More news about: Corero Network Security
Mar 04, 2026, 11:15 ET BCEN's Critical Care Ground Transport Nursing Specialty Certification Turns 20
past 20 years, CTRN certification has helped define and advance ground critical care transport nursing as a specialty," said Allen C. Wolfe Jr., MSN, CNS, APRN, CFRN, CCRN, CTRN, TCRN, CMTE, FAASTN, BCEN board of directors immediate past chairperson, and senior director of clinical education and critical
More news about: Board of Certification for Emergency Nursing
Mar 04, 2026, 09:00 ET REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: Levi & Korsinsky, LLP
Mar 03, 2026, 09:04 ET CenExel Clinical Research Network Expands Capabilities Across Sites Nationwide
psychedelic dosing room and Schedule I drug storage roomInfusion capabilitiesAccess to top-rated imaging vendorsDedicated CNS prescreening and intake spaceState-of-the-art pharmacy and laboratory facilitiesFull patient kitchen, dining area and common spacesThe
More news about: CenExel Clinical Research
Mar 03, 2026, 09:00 ET Shareholders that lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class Action - RGNX
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Mar 03, 2026, 06:30 ET Immunic to Participate in Investor Conferences in March
[email protected] 17-18: Stifel 2026 Virtual CNS Forum. Dr. Vitt and Mr. Tardio will participate in a fireside chat on Wednesday, March 18, at 4:00 pm ET at this virtual conference. A webcast will
More news about: Immunic, Inc.
Mar 02, 2026, 17:58 ET REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses
Plaintiff alleges that in truth, defendants were aware of the serious safety issues relating to the RGX-111 study including the potential for CNS neoplasm and in November 2023 abruptly decided to de-prioritize its second-most advanced clinical candidate, RGX-111, and seek "strategic alternatives"
More news about: Robbins LLP
Mar 02, 2026, 16:05 ET Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About IBTROZI IBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough
More news about: Nuvation Bio Inc.
Mar 02, 2026, 16:05 ET Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
significant unmet medical need for a novel efficacious antiseizure medicine that is easy-to-use, does not burden patients with central nervous system (CNS) side effects like dizziness and somnolence, and does not make their comorbidities worse. In fact, we were very excited to report preliminary data demonstrating
More news about: Biohaven Ltd.
Mar 02, 2026, 14:46 ET The Multiple Sclerosis Association of America (MSAA) Launches Campaign Focused on Self-Advocacy Strategies in Recognition of MS Awareness Month
SclerosisMultiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America
Mar 02, 2026, 09:10 ET XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
patients worldwide.Standing at the Forefront of iPSC-derived Cell Therapies for CNS Diseases This pipeline extension into MSA-P naturally taps into XellSmart's expertise in CNS diseases, evidenced by its multiple cleared "China or global first" INDs. Overall, nine INDs from
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Mar 02, 2026, 08:00 ET Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Feb 27, 2026, 11:44 ET Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
multimedia:https://www.prnewswire.com/news-releases/psychedelic-biotechs-push-toward-phase-3-five-companies-advancing-cns-treatments-302699781.html
More news about: Equity Insider
Feb 27, 2026, 11:28 ET Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla USA Inc.
Feb 27, 2026, 09:20 ET RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP